Phase 3 Readout

IMTX: Phase 3 Topline: A Prospective, Multicenter, Open-label, Randomized, Actively Controlled, Parallel-group Phase 3 Clin

Name: Phase 3 Topline: A Prospective, Multicenter, Open-label, Randomized, Actively Controlled, Parallel-group Phase 3 Clin
Start: 2031-10-01
End: 2031-10-01

October 1, 2031. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: October 1, 2031
Company: Immatics N.V. (IMTX)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: A Prospective, Multicenter, Open-label, Randomized, Actively Controlled, Parallel-group Phase 3 Clin

October 1, 2031

IMTX overview →

Company: Immatics N.V. (IMTX)
Indication: Melanoma, Cutaneous Malignant